252 related articles for article (PubMed ID: 26585358)
1. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN; Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2015 Dec; 41(10):935-50. PubMed ID: 26585358
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
[TBL] [Abstract][Full Text] [Related]
4. SNPs and taxane toxicity in breast cancer patients.
Bosó V; Herrero MJ; Santaballa A; Palomar L; Megias JE; de la Cueva H; Rojas L; Marqués MR; Poveda JL; Montalar J; Aliño SF
Pharmacogenomics; 2014; 15(15):1845-58. PubMed ID: 25495407
[TBL] [Abstract][Full Text] [Related]
5. Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Demurtas S; La Verde N; Rota S; Casazza G; Montrasio C; Cheli S; Cona MS; Dalu D; Fasola C; Ferrario S; Filipazzi V; Gambaro A; Tosca N; Clementi E
Pharmacogenomics J; 2021 Aug; 21(4):491-497. PubMed ID: 33649523
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Leskelä S; Jara C; Leandro-García LJ; Martínez A; García-Donas J; Hernando S; Hurtado A; Vicario JC; Montero-Conde C; Landa I; López-Jiménez E; Cascón A; Milne RL; Robledo M; Rodríguez-Antona C
Pharmacogenomics J; 2011 Apr; 11(2):121-9. PubMed ID: 20212519
[TBL] [Abstract][Full Text] [Related]
7. Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.
Herrero Rivera D; Vacas CG; Kovandzic LM; Vázquez JP; Alonso LA; González BM; Aragón VC; Grande E; Caro RL; Virizuela Echaburu JA; Rodríguez Moreno JF; Etxebarria AA; Rodríguez-Antona C; Durán I
Pharmacogenomics; 2022 Jul; 23(11):627-638. PubMed ID: 35880554
[No Abstract] [Full Text] [Related]
8. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
de Graan AJ; Elens L; Sprowl JA; Sparreboom A; Friberg LE; van der Holt B; de Raaf PJ; de Bruijn P; Engels FK; Eskens FA; Wiemer EA; Verweij J; Mathijssen RH; van Schaik RH
Clin Cancer Res; 2013 Jun; 19(12):3316-24. PubMed ID: 23640974
[TBL] [Abstract][Full Text] [Related]
9. Targeted Sequencing Reveals Low-Frequency Variants in
Apellániz-Ruiz M; Tejero H; Inglada-Pérez L; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; Castelo B; Redondo A; García-Donás J; Romero-Laorden N; Sereno M; Merino M; Currás-Freixes M; Montero-Conde C; Mancikova V; Åvall-Lundqvist E; Green H; Al-Shahrour F; Cascón A; Robledo M; Rodríguez-Antona C
Clin Cancer Res; 2017 Mar; 23(5):1227-1235. PubMed ID: 27582484
[No Abstract] [Full Text] [Related]
10. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.
Gréen H; Khan MS; Jakobsen-Falk I; Åvall-Lundqvist E; Peterson C
J Pharm Sci; 2011 Oct; 100(10):4205-9. PubMed ID: 21702053
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
Jabir RS; Naidu R; Annuar MA; Ho GF; Munisamy M; Stanslas J
Pharmacogenomics; 2012 Dec; 13(16):1979-88. PubMed ID: 23215890
[TBL] [Abstract][Full Text] [Related]
14. SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma.
Duran I; Hagen C; Arranz JÁ; Apellaniz-Ruiz M; Pérez-Valderrama B; Sala N; Lainez N; García-Del Muro X; Noguerón E; Climent MÁ; Maroto P; Font A; García-Donas J; Gallardo E; López-Criado P; González Del Alba A; Sáez MI; Vázquez S; Luque R; Rodríguez-Antona C
Pharmacogenomics; 2016 Apr; 17(5):463-71. PubMed ID: 27020167
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
[TBL] [Abstract][Full Text] [Related]
16. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
17. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
Yamaguchi H; Hishinuma T; Endo N; Tsukamoto H; Kishikawa Y; Sato M; Murai Y; Hiratsuka M; Ito K; Okamura C; Yaegashi N; Suzuki N; Tomioka Y; Goto J
Int J Gynecol Cancer; 2006; 16(3):979-85. PubMed ID: 16803472
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]